Coronavirus spike glycoprotein receptor binding domain and its use
Recombinant polypeptides with specific amino acid substitutions in coronavirus spike glycoprotein RBD and SD1 domains address the need for improved coronavirus vaccines by enhancing thermal stability and antigenicity, thereby improving vaccine efficacy.
JP2026517799APending Publication Date: 2026-06-02ICOSAVAX INC
Patent Information
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- ICOSAVAX INC
- Filing Date
- 2024-05-10
- Publication Date
- 2026-06-02
Smart Images
Figure 2026517799000001_ABST
Abstract
This disclosure relates to polypeptides comprising an antigenic fragment of the receptor-binding domain (RBD) of coronavirus spike glycoprotein, the protein nanostructure thereof, methods for producing the same, and their prophylactic and therapeutic uses. In some embodiments, the antigenic fragment comprises coronavirus subdomain 1 (SD1). In one embodiment, this disclosure provides a recombinant polypeptide comprising an antigenic fragment of coronavirus spike glycoprotein comprising the receptor-binding domain (RBD) and optionally coronavirus subdomain 1 (SD1). In some embodiments, the antigenic fragment of the polypeptide comprises or is essentially derived from RDB-SD1.
Need to check novelty before this filing date? Find Prior Art